216 related articles for article (PubMed ID: 36403110)
21. Management of AL amyloidosis in 2020.
Palladini G; Milani P; Merlini G
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):363-371. PubMed ID: 33275753
[TBL] [Abstract][Full Text] [Related]
22. Daratumumab in AL amyloidosis.
Wechalekar AD; Sanchorawala V
Blood; 2022 Dec; 140(22):2317-2322. PubMed ID: 35507692
[TBL] [Abstract][Full Text] [Related]
23. IgG,kappa monoclonal gammopathy of unknown significance with AL amyloidosis simulating giant cell arteritis.
Pompilian VM; Tănăseanu Ş; Badea C; Zurac S; Socoliuc C; Badelita S; Botez E; Antohe M
Rom J Intern Med; 2017 Sep; 55(3):179-182. PubMed ID: 28467313
[TBL] [Abstract][Full Text] [Related]
24. Cardiac Amyloidosis Presenting with Pre-Excitation Syndrome, Heart Failure, and Severe Factor X Deficiency as Part of Systemic Amyloid Light-Chain (AL) Amyloidosis - A Fatal Combination.
Almasri H; Almeer A; Awouda S; Hamid O; Sardar S; Anwer Z; Ibrahim F; Soliman D; Kandathil Y; Abu-Tineh M; Alabdul Razzak I; Alazawi SH
Am J Case Rep; 2021 Aug; 22():e933398. PubMed ID: 34413281
[TBL] [Abstract][Full Text] [Related]
25. Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study.
Kikukawa Y; Yuki H; Hirata S; Ide K; Nakata H; Miyakawa T; Matsuno N; Nosaka K; Yonemura Y; Kawaguchi T; Hata H; Mitsuya H; Okuno Y
Int J Hematol; 2015 Feb; 101(2):133-9. PubMed ID: 25430082
[TBL] [Abstract][Full Text] [Related]
26. Characterization of isolated amyloid myopathy.
Liewluck T; Milone M
Eur J Neurol; 2017 Dec; 24(12):1437-1445. PubMed ID: 28888072
[TBL] [Abstract][Full Text] [Related]
27. Amyloid myopathy: characteristic features of a still underdiagnosed disease.
Chapin JE; Kornfeld M; Harris A
Muscle Nerve; 2005 Feb; 31(2):266-72. PubMed ID: 15478123
[TBL] [Abstract][Full Text] [Related]
28. [Treatment strategy for immunoglobulin light chain amyloidosis].
Fuchida SI
Rinsho Ketsueki; 2021; 62(8):1160-1166. PubMed ID: 34497203
[TBL] [Abstract][Full Text] [Related]
29. Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2018 Sep; 93(9):1169-1180. PubMed ID: 30040145
[TBL] [Abstract][Full Text] [Related]
30. How I treat AL amyloidosis.
Palladini G; Merlini G
Blood; 2022 May; 139(19):2918-2930. PubMed ID: 34517412
[TBL] [Abstract][Full Text] [Related]
31. Axial myopathy due to primary amyloidosis.
Friedman Y; Paul JT; Turley J; Hazrati LN; Munoz D
Muscle Nerve; 2007 Oct; 36(4):542-6. PubMed ID: 17405139
[TBL] [Abstract][Full Text] [Related]
32. [Efficacy and safety of daratumumab in the treatment of advanced light chain amyloidosis].
Shen KN; Miao HL; Gao YJ; Cao XX; Zhou DB; Su W; Li J
Zhonghua Xue Ye Xue Za Zhi; 2022 Jan; 43(1):31-34. PubMed ID: 35231990
[No Abstract] [Full Text] [Related]
33. Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria.
Kimmich CR; Terzer T; Benner A; Dittrich T; Veelken K; Carpinteiro A; Hansen T; Goldschmidt H; Seckinger A; Hose D; Jauch A; Wörner S; Beimler J; Müller-Tidow C; Hegenbart U; Schönland SO
Blood; 2020 Apr; 135(18):1517-1530. PubMed ID: 32107537
[TBL] [Abstract][Full Text] [Related]
34. Systemic Immunoglobulin Light Chain Amyloidosis-Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome.
Muchtar E; Derudas D; Mauermann M; Liewluck T; Dispenzieri A; Kumar SK; Dingli D; Lacy MQ; Buadi FK; Hayman SR; Kapoor P; Leung N; Chakraborty R; Gonsalves W; Russell S; Lust JA; Lin Y; Go RS; Zeldenrust S; Kyle RA; Rajkumar SV; Gertz MA
Mayo Clin Proc; 2016 Oct; 91(10):1354-1361. PubMed ID: 27712634
[TBL] [Abstract][Full Text] [Related]
35. Diagnosis and Treatment of AL Amyloidosis.
Palladini G; Milani P
Drugs; 2023 Feb; 83(3):203-216. PubMed ID: 36652193
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of Daratumumab-based Regimens in Pretreated Light Chain (AL) Amyloidosis: A Systematic Review.
Ehsan H; Rafae A; Masood A; Wahab A; Sana MK; Ansar I; Neupane K; Umar A; Ehsan A; Hashmi H
Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e285-e292. PubMed ID: 34879994
[TBL] [Abstract][Full Text] [Related]
37. Coexisting sporadic late onset nemaline myopathy and AL amyloid myopathy - incidental or related?
Moshe-Lilie O; Banks G; Medvedova E; Masri A; Chahin N
Neuromuscul Disord; 2022 Jun; 32(6):533-538. PubMed ID: 35550111
[TBL] [Abstract][Full Text] [Related]
38. Complete remission of both immunoglobulin light chain amyloidosis and psoriasis after autologous hematopoietic stem cell transplantation: A case report.
Chen W; Ren G; Zuo K; Huang X
Medicine (Baltimore); 2018 Dec; 97(50):e13589. PubMed ID: 30558027
[TBL] [Abstract][Full Text] [Related]
39. Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed/refractory AL amyloidosis.
Cohen OC; Brodermann MH; Blakeney IJ; Mahmood S; Sachchithanantham S; Ravichandran S; Law S; Lachmann HJ; Whelan CJ; Popat R; Rabin N; Yong K; Kyriakou C; Shah R; Cheesman S; Worthington S; Hawkins P; Gillmore JD; Wechalekar AD
Amyloid; 2020 Sep; 27(3):200-205. PubMed ID: 32408823
[No Abstract] [Full Text] [Related]
40. Management of AL amyloidosis in 2020.
Palladini G; Milani P; Merlini G
Blood; 2020 Dec; 136(23):2620-2627. PubMed ID: 33270858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
